FORT LAUDERDALE, Fla., Nov. 4, 2008 (GLOBE NEWSWIRE) -- MAKO Surgical Corp. (NasdaqGM:MAKO - News) announced today that Thomas M. Coon, M.D. of St. Elizabeth Community Hospital will present a live surgical webcast of a MAKOplasty(r) partial knee resurfacing procedure, which utilizes robotic arm technology, on December 1st at 3:00 p.m. PST.

MAKOplasty(r) offers a new treatment option for those who suffer with early to mid-stage knee osteoarthritis. It is enabled by the MAKO Tactile Guidance System(tm) (TGS(tm)), a surgeon-interactive tactile robotic arm and 3-D virtual visualization system that delivers consistent reproducible precision and eliminates many of the challenges of manual partial knee procedures.

The TGS(tm) allows the surgeon to make a pre-surgical plan that details the technique for bone preparation and implant positioning using a CT scan of the patient's knee. During the MAKOplasty(r) procedure the system creates a three-dimensional live-action, virtual view of the patient's bone surface and correlates the image to the pre-programmed surgical plan. As the surgeon uses the robotic arm, its tactile, acoustic and visual feedback limits the bone preparation to the diseased areas and provides for more optimal implant positioning, placement and results.

The MAKOplasty(r) partial knee resurfacing procedure will be webcast on OR-Live, Inc., an Internet broadcasting company which creates live and on-demand video-based communications solutions for clients in the healthcare industry. It has developed more than 600 live and on-demand events and more than 2,000 hours of programming.

About MAKO Surgical Corp.

MAKO Surgical Corp. is a medical device company that markets both its advanced robotic-arm solution and its proprietary implants for minimally invasive orthopedic knee procedures. The MAKO Tactile Guidance System(tm) (TGS(tm)) is a surgeon-interactive tactile platform that incorporates a robotic arm and patient-specific visualization technology and prepares the knee joint for the insertion and alignment of MAKO's resurfacing implants through a minimal incision. The FDA-cleared TGS allows surgeons to provide a precise, consistently reproducible tissue-sparing, bone resurfacing procedure called MAKOplasty(r) to a large, yet underserved patient-specific population suffering from early to mid-stage osteoarthritic knee disease. MAKO has an intellectual property portfolio of more than 200 licensed or owned patents and patent applications relating to the areas of computer assisted surgery, haptics, robotics and implants. Additional information can be found at http://www.makosurgical.com.

          MAKO Surgical Corp.
          Cynthia M. Kalb
          954-927-2044 x426
          ckalb@makosurgical.com